health and wellness2 years ago
FDA Approves First Targeted Therapy for HER2-Low Breast Cancer
Today, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic...